Today, women with estrogen-sensitive breast cancer receive anti-hormonal therapy. Researchers now show that postmenopausal women with low-risk tumors have a long-term benefit for at least 20 years, while the benefit was more short-term for younger women with similar tumor characteristics who had not yet gone through the menopause.
More...
Threaded Mode